Statiny i risk vozniknoveniya novykh sluchaev sakharnogo diabeta: sootnoshenie riska i pol'zy. Sovremennye predstavleniya o tselevykh urovnyakh lipidov u patsientov s sakharnym diabetom


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, data on the increase of risk of new diabetes cases in patients receiving statins appear in the literature. This review examines recent studies devoted to this problem, the possible mechanisms of impaired glucose metabolism against the background of statin therapy. Target levels of atherogenic lipids in patients with diabetes, presented in the current national and European guidelines, are analyzed.

Full Text

Restricted Access

References

  1. Navarese E.P., Buffon A., Andreotti F., et al. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am. J. Cardiol. 2013 Jan 24. pii: S0002-9149(12)02640-9. dor.10.1016/j.amj-card.2012.12.037. [Epub ahead of print].
  2. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001; 507(3): 357-61.
  3. Драпкина О.М. Статины и риск развития сахарного диабета. Рациональная фармакотерапия в кардиологии. 2013; 9(4): 444-447.
  4. Драпкина О.М. Статины и сахарный диабет: риск и польза. Кардиоваскулярная терапия и профилактика. 2012; 11(6): 85-90.
  5. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368: 1155-63.
  6. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-30.
  7. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet. 2003; 361: 1149-58.
  8. Sukhija R., Prayaga S., Marashdeh M., et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J. Investig Med. 2009; 57: 495-99.
  9. Preiss D., Sreenivasa Rao Kondapally Seshasai, Welsh P., et al. Risk of Incident Diabetes With Intensive-Dose Compared With ModerateDose Statin Therapy A Meta-analysis. JAMA. 2011; 305(24): 2556-64.
  10. Culver A., Ockene I., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern. Med. 2012; 172: 144-52.
  11. Swapnil N. Rajpathak, Dharam J. Kumbhani, Crandall J, et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care. 2009; 32(10): 1924-29.
  12. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716): 735-42.
  13. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359: 2195-207.
  14. Waters D.D. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. JACC. 2011; 57: 1535-45.
  15. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103: 357-62.
  16. Rautio N., Jokelainen J., Oksa H., et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012; 2: e001472.
  17. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78.
  18. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-81.
  19. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371: 117-25.
  20. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
  21. Kosaka K., Noda M., Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res. Clin. Pract. 2005; 67: 152-62.
  22. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care. 1997; 20: 537-44.
  23. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006; 49: 289-97.
  24. Tuomilehto J., Lindstöm J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344: 1343-50.
  25. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study. Diabet Med. 2012; 29: 628-31.
  26. Sampson U.K., Linton M.F., Fazio S. Are statins diabetogenic? Curr Opin. Cardiol. 2011; 26: 342-47.
  27. Baker W.L., Talati R., White C.M., et al. Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2010; 87: 98-7.
  28. Jula A., Marniemi J., Huupponen R., et al. Effects of diet and simvastatin on serum lipids, insulin and antioxidants in hypercholesterolemic men. A randomized controlled trial. JAMA. 2002; 287: 598-605.
  29. Ohrvall M., Lithell H., Johansson J., et al. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995; 44: 212-17.
  30. Stewart M.W., Dyer R.G., Alberti K.G., et al. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidemia. Diabet Med. 1995; 12: 250-57.
  31. Hwu C.M., Kwok C.F., Chen H.S., et al. Lack of effects of simvastatin on insulin sensitivity in type 2 diabetic patients with hypercholesterolemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med. 1999; 16: 749-54.
  32. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000; 150: 121-27.
  33. Koh K.K., Quon M.J., Han S.H., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009; 204(2): 483-90.
  34. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clinical Diabetes. 2009; 27(1): 4-16.
  35. Wang K., Liu C., Chao T., Huang C., Wu C., Chen S., et al. Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 2012; 60: 1231-38.
  36. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). М., 2012.
  37. EAS/ESC Guidelines for the management of dyslipidemias. Eur. Heart J. 2011; 32: 1769-818.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies